2024
DOI: 10.1186/s12882-024-03499-w
|View full text |Cite
|
Sign up to set email alerts
|

Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening

Zewei Chen,
Bo Yin,
Juan Jiao
et al.

Abstract: Fabry disease (FD) is an uncommon, X-linked, lysosomal storage disease that causes defects in the glycosphingolipid metabolic pathway due to deficient or absent lysosomal α-galactosidase (α-Gal A) activity. This leads to the accumulation of globotriaosylceramide (GL-3) within lysosomes in a wide range of cells, including endothelial, cardiac, renal, and corneal cells, and consequently, the progressive appearance of clinical symptoms in target organs. Enzyme replacement therapy (ERT), which involves the exogeno… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…Diagnostic methods include enzyme assays, genetic testing, and imaging studies [ 8 , 9 ]. Differential diagnoses can include other lysosomal storage disorders, chronic kidney disease of unknown origin, and various cardiovascular conditions [ 10 ]. Treatment options for Fabry disease include enzyme replacement therapy (ERT), chaperone therapy, and emerging gene therapies [ 6 - 8 ].…”
Section: Introductionmentioning
confidence: 99%
“…Diagnostic methods include enzyme assays, genetic testing, and imaging studies [ 8 , 9 ]. Differential diagnoses can include other lysosomal storage disorders, chronic kidney disease of unknown origin, and various cardiovascular conditions [ 10 ]. Treatment options for Fabry disease include enzyme replacement therapy (ERT), chaperone therapy, and emerging gene therapies [ 6 - 8 ].…”
Section: Introductionmentioning
confidence: 99%